GP collective action in Kent has led to an agreement from the ICB to fund new locally-commissioned services, including for ...

在全球生物医药领域，多肽和寡核苷酸（TIDES）疗法近期迎来了一系列突破性进展。诺华（Novartis）公司研发的siRNA降胆固醇药物——英克司兰钠（inclisiran），在亚洲的3期临床研究中显示出色的效果，药物能够在一年内仅需注射两次，帮助近80%的患者实现低密度脂蛋白胆固醇（LDL-C）达标。而177Lu-edotreotide作为一种靶向放射性疗法，最近也取得了重要成果，有望在治疗特定 ...

Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.' ...

2025 to demonstrate acceleration of commercial growth through double-stranded RNA ligase and GLP-grade siRNA material; expect to secure GMP scale-up partner REDWOOD CITY, Calif., Feb. 27, 2025 ...

Ohio: Once pegged as a blockbuster medicine for lowering LDL, long-acting small interfering RNA, Inclisiran failed to find any place in the recently released American Association of Clinical ...

Patients should be informed about potential harms such as gout, cholelithiasis, and tendon rupture, necessitating a shared decision-making approach. Inclisiran Loses Favor There is currently ...

The usual Leqvio (inclisiran) dosage for certain kinds of high cholesterol is 284 milligrams per 1.5 milliliters (mg/mL). Specific dosages may vary depending on factors like your individual ...

They have been joined by inclisiran (Leqvio). For people like you, who cannot tolerate a statin, these medications offer a different way of managing blood lipids. You can learn more about these ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Inclisiran – now given the trade name Leqvio – has been recommended for approval by the CHMP as a treatment for hypercholesterolaemia or mixed dyslipidaemia, two common forms of elevated ...